[go: up one dir, main page]

WO2014128875A1 - Instrument pour traitement médical - Google Patents

Instrument pour traitement médical Download PDF

Info

Publication number
WO2014128875A1
WO2014128875A1 PCT/JP2013/054272 JP2013054272W WO2014128875A1 WO 2014128875 A1 WO2014128875 A1 WO 2014128875A1 JP 2013054272 W JP2013054272 W JP 2013054272W WO 2014128875 A1 WO2014128875 A1 WO 2014128875A1
Authority
WO
WIPO (PCT)
Prior art keywords
catheter
distal end
substance
central axis
living tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2013/054272
Other languages
English (en)
Japanese (ja)
Inventor
谷田部輝幸
栗田朋香
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo Corp
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Priority to PCT/JP2013/054272 priority Critical patent/WO2014128875A1/fr
Publication of WO2014128875A1 publication Critical patent/WO2014128875A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
    • A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
    • A61M25/0026—Multi-lumen catheters with stationary elements
    • A61M25/003—Multi-lumen catheters with stationary elements characterized by features relating to least one lumen located at the distal part of the catheter, e.g. filters, plugs or valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
    • A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
    • A61M25/0026—Multi-lumen catheters with stationary elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/0102—Insertion or introduction using an inner stiffening member, e.g. stylet or push-rod
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
    • A61M2025/0042—Microcatheters, cannula or the like having outside diameters around 1 mm or less
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0693—Brain, cerebrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
    • A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
    • A61M25/0026—Multi-lumen catheters with stationary elements
    • A61M25/0032—Multi-lumen catheters with stationary elements characterized by at least one unconventionally shaped lumen, e.g. polygons, ellipsoids, wedges or shapes comprising concave and convex parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0097—Catheters; Hollow probes characterised by the hub

Definitions

  • the present invention relates to a medical device used for continuous delivery of a substance into a living tissue, particularly for increased convection delivery of a therapeutic substance into the brain parenchyma.
  • Non-patent Document 1 glioblastoma, anaplastic astrocytoma, etc.
  • various therapies such as chemotherapy, immunotherapy, gene therapy, molecular target therapy, etc.
  • Attempts have been made to improve the outcome of malignant brain tumors, including glioma.
  • the most malignant glioblastoma has a low 5-year survival rate of about 7%, and still has the poorest prognosis among all cancers (Non-patent Document 1).
  • BBB blood brain barrier
  • a convection-enhanced delivery (CED) method has been devised as a new drug administration method for overcoming the problems of chemotherapy for malignant glioma as described above (see, for example, Patent Document 1). ).
  • the CED method is local chemotherapy in which a drug is actively infused from a catheter placed stereotaxically in the brain parenchyma using a microinfusion pump.
  • the distribution of the drug depends on the diffusion of the substance, whether it is intracavitary administration to the tumor excision cavity or a local chemotherapeutic agent placed in the brain.
  • the diffusion of substances is defined by concentration gradients and tissue properties, and even a low-molecular compound with good diffusivity is considered to have a range of only a few millimeters due to absorption and metabolism in capillaries. This is inadequate for 80-90% of recurrences of malignant gliomas occurring at sites within 2 cm from the initial lesion (see Non-Patent Document 2).
  • the pressure gradient during the injection is maintained to induce a bulk flow between the cerebral layers to enhance the diffusion of the injected substance. Therefore, compared with the conventional local administration method, the drug can be distributed more uniformly and at a high concentration over a wide range.
  • the distribution of the drug in the brain can be controlled by the injection volume and the injection speed, and it is possible to reduce the dose compared to the systemic administration by vein, so that systemic side effects can be suppressed to a level where there is no problem. Is possible.
  • drugs that can be administered by the CED method, and various drugs have been tried in rat brain tumor transplantation models, and their effectiveness has been reported. Because of these advantages, the CED method is expected as a treatment method for not only brain tumors but also Parkinson's disease, Alzheimer's disease and epilepsy.
  • Patent Document 1 discloses a cannula having a step structure with an outer diameter changing near the end and a drug delivery system as a catheter for preventing a drug backflow.
  • a drug having a substantially constant inner diameter is provided with a multi-stage structure in which the outer diameter decreases from the proximal end to the distal end, thereby preventing backflow of the drug.
  • the cannula described in Patent Document 1 has a thin outer diameter so as to suppress brain tissue damage and backflow along the catheter. Therefore, the cannula is easily bent and is not easily inserted accurately into a target site. Absent.
  • the present invention solves the above-described problems, and a catheter that is inserted into a non-lumen region of a living tissue and delivers a substance into the living tissue can be accurately transferred to a target site without affecting the living tissue as much as possible. It aims at providing the medical instrument which can be made to reach.
  • a medical instrument according to the present invention that achieves the above object is a medical instrument for inserting a substance into a living tissue by being inserted into a non-luminal region of the living tissue, and delivering the substance into the living tissue.
  • a catheter formed with a delivery lumen disposed through the central axis and at least two distal closure lumens closed at the distal end, and inserted into the distal closure lumen from the proximal end side of the catheter And at least two core members.
  • the delivery lumen penetrates on the central axis so that the substance from the catheter tip can be penetrated. Stiffness can be imparted to the catheter by the core portion inserted through the distal end closing lumen while maintaining the uniformity of administration and delivery.
  • the distal end closing lumen is not disposed on the central axis, but by providing a plurality of the lumens, it is possible to suppress a deviation in the ease of bending due to the direction of the acting force and to secure sufficient rigidity, and to raise the catheter to the target site. It becomes possible to reach the accuracy.
  • the tip closing lumen is closed, it is possible to prevent air from entering the living tissue, and tissue fluid can flow into the tip closing lumen even if the core is removed from the tip closing lumen. Therefore, the load on the living tissue can be suppressed as much as possible.
  • At least two of the core members are connected to each other at the base end, they can be operated simultaneously while maintaining the positional relationship of the plurality of core members.
  • the catheter can reach the target site with high accuracy.
  • the number of the core parts is 2 to 4, it is possible to efficiently suppress the deviation of the bending ease due to the direction of the acting force.
  • the catheter can be given the maximum rigidity.
  • the core member has a sufficient bending rigidity if the length in the radial direction from the central axis is shorter than the length in the direction perpendicular to the radial direction in a cross section perpendicular to the central axis of the catheter.
  • the delivery lumen for delivering the substance can be secured widely.
  • the catheter has a tapered portion whose outer diameter gradually decreases toward the distal end side between the distal end portion and the proximal end portion, the catheter is inserted so as to push out while suppressing damage to living tissue as much as possible.
  • the tapered portion can suppress the backflow of the substance along the outer surface of the catheter.
  • the core is made of a non-magnetic material, halation can be prevented during MRI contrast.
  • the catheter can be inserted with high precision to the target position in the area where the tumor is formed, and the substance can be effectively delivered to the tumor. Is possible.
  • the catheter is used for increased convection delivery of a substance to the brain, it becomes possible to effectively deliver the substance to the brain by inserting the catheter to the target position of the brain with high accuracy.
  • FIG. 3 is a cross-sectional view taken along line 3-3 in FIG. It is the schematic which shows at the time of delivering a therapeutic substance in a brain using the medical device which concerns on embodiment.
  • It is sectional drawing which shows the modification of a medical instrument (A) shows the example in which two tip closing lumens are provided, (B) shows the example in which three tip closing lumens are provided.
  • It is sectional drawing which shows the other modification of a medical instrument (A) shows the example in which two tip closing lumens are provided, (B) shows the example in which three tip closing lumens are provided.
  • proximal end side the proximal side of the catheter
  • distal end side the inserted side
  • catheter represents one including a tube used for medical purposes.
  • the catheter is not limited to treatment, and may be for examination, for example.
  • the medical device 1 is used in a convection-enhanced delivery (CED) method for delivering a therapeutic substance to, for example, a brain tumor in the brain.
  • CED convection-enhanced delivery
  • the CED method is a method in which a small amount of drug is injected while being actively and continuously pressurized through a catheter 10 stereotaxically placed in the brain parenchyma, thereby maintaining a pressure gradient and generating convection.
  • Is a local chemotherapy that uses the flow generated by the drug to distribute the drug in a wide and high concentration in the tissue gap.
  • the medical device 1 includes a tubular catheter 10 that is inserted into the brain parenchyma to deliver a therapeutic substance, and a stylet 20 that can be inserted into the catheter 10. ing.
  • the catheter 10 has a tubular portion 30 that is formed in a long shape and has a plurality of lumens formed therein, and a catheter hub portion 40 that is fixed to the proximal end of the tubular portion 30.
  • a delivery lumen 31 for delivering a therapeutic substance on the central axis X of the catheter 10 and four distal end closing lumens 32 whose distal end sides are closed are formed inside the tubular portion 30 and the catheter hub portion 40.
  • the delivery lumen 31 is located on the central axis X of the catheter 10 and opens at a distal end opening 33 formed on the most distal surface of the tubular portion 30.
  • Each distal end closing lumen 32 extends to the vicinity of the most distal end of the tubular portion 30, and the distal end side is closed without being released to the outside.
  • All the four distal end closing lumens 32 are formed in parallel and in the same shape, and are arranged evenly in the circumferential direction so as to surround the delivery lumen 31 around the central axis X of the catheter 10, that is, every 90 °.
  • the delivery lumen 31 and the four distal closing lumens 32 are both formed in a circular shape in a cross section orthogonal to the central axis X of the catheter 10.
  • the outer diameter D of the distal end portion of the catheter 10 is preferably 0.5 to 3.0 mm, but is not limited thereto.
  • the catheter 10 is made of a flexible material, and for example, a polyurethane elastomer, a polyamide elastomer, a polyester elastomer, a polyvinyl chloride, a silicone elastomer, or the like can be suitably applied thereto, but is not limited thereto.
  • the catheter hub portion 40 is connected to the proximal end of the tubular portion 30 and includes a liquid feeding tube 41 for supplying a therapeutic substance to the delivery lumen 31 from the outside.
  • the four distal closing lumens 32 are opened at a proximal opening 42 formed on the proximal surface of the catheter hub 40.
  • the liquid delivery tube 41 can be fitted with a tube tip 51 of a syringe 50 for injecting a therapeutic substance.
  • a check valve, a three-way stopcock, or the like may be provided at the end of the liquid feeding tube 41 to which the syringe 50 is connected.
  • the syringe 50 is attached to a microinjection pump 55 (see FIG. 4) and can deliver a therapeutic substance at a preset injection amount and injection rate.
  • the stylet 20 functions as a core material that gives rigidity to the tubular portion 30 having flexibility when the tubular portion 30 of the catheter 10 is inserted into the brain parenchyma, and extends in a straight line. And four stylet main body portions 21 (core member portions) and a stylet hub portion 22.
  • Each of the four stylet main body portions 21 can be inserted into the distal end closing lumen 32 from the proximal end opening 42, and all of the four stylet main body portions 21 are formed in parallel and in the same shape, and when inserted into the distal end closing lumen 32, the catheter 10. Centered on the central axis X of the delivery lumen 31 so as to surround the delivery lumen 31 evenly in the circumferential direction.
  • the four distal end closing lumens 32 are each formed in a circular shape that can be inserted into the distal end closing lumen 32 in a cross section orthogonal to the central axis X of the catheter 10.
  • the stylet body 21 is preferably formed of a non-magnetic material (a material that is not a ferromagnetic material) that is unlikely to cause halation during MRI (magnetic resonance imaging) imaging.
  • a non-magnetic material a material that is not a ferromagnetic material
  • titanium, ceramic, carbon fiber Although it is made of reinforced plastic (CFRP), Co-based alloy, nonmagnetic stainless steel or the like, it is not limited to this.
  • the stylet hub portion 22 has a base end portion of the stylet main body portion 21 fixed thereto, maintains the positional relationship of the four stylet main body portions 21, and allows the four stylet main body portions 21 to be operated simultaneously. Plays.
  • the stylet hub portion 22 contacts the catheter hub portion 40 when the stylet main body portion 21 is inserted to the most distal end (backmost) of the distal end closing lumen 32 of the catheter 10.
  • the stylet hub portion 22 also functions as a portion to be gripped by the operator when the stylet main body portion 21 is inserted through the catheter 10 and when the catheter 10 is removed.
  • the stylet hub portion 22 is formed as a separate body from the stylet main body portion 21, but may be integrally formed.
  • therapeutic substances include anticancer agents, more specifically, alkylating agents such as nimustine, ranimustine, and temozolomide, platinum preparations such as cisplatin, oxaliplatin, and dahaplatin, sulfazine, methotrexate, fluorouracil, fructocin, azathioprine, and pentostatin.
  • the stylet hub 22 is gripped, the stylet main body 21 is inserted through the proximal opening 42 of the catheter hub 40, and the stylet hub 22 is brought into contact with the catheter hub 40. Thereby, the front-end
  • the syringe 50 is connected to the liquid feeding tube 41. If a check valve or a three-way stopcock is provided at the end of the liquid feeding tube 41, the liquid feeding tube 41 may be connected to the syringe 50 after the catheter 10 is placed in the living tissue.
  • the catheter 10 with the stylet 20 inserted is grasped, and the catheter 10 is inserted into the brain parenchyma until the tip of the tubular portion 30 reaches the brain tumor in the brain parenchyma or in the vicinity of the brain tumor.
  • the stylet main body portion 21 is inserted into the tubular portion 30 of the catheter 10, the flexible and thin tubular portion 30 is given rigidity so that it is difficult to bend and can reach the target position with high accuracy.
  • the four stylet main body portions 21 are not arranged on the central axis X of the catheter 10, but are arranged uniformly in the circumferential direction so as to surround the delivery lumen 31 and have the same shape. The deviation of the ease of bending due to the direction of the acting force is suppressed as much as possible, and sufficient rigidity is obtained.
  • the stylet hub portion 22 is grasped and the stylet main body portion 21 is pulled out from the tip closing lumen 32.
  • the tubular portion 30 of the catheter 10 can be flexibly deformed in response to the movement of the living body, and the load on the living tissue during long-time use can be reduced as much as possible. Since the distal end side of the distal end closing lumen 32 is closed, it is possible to prevent air from being mixed into the living body, and even if the stylet hub portion 22 is removed from the distal end closing lumen 32, the tissue fluid in the living body remains at the distal end closing lumen. 32, the load on the living tissue can be suppressed as much as possible.
  • the therapeutic substance is supplied from the syringe 50, and the therapeutic substance is released from the distal end opening 33 of the catheter 10 through the liquid feeding tube 41 and the delivery lumen 31 at a predetermined injection amount and injection rate, and directly to the brain tumor. And it is administered and delivered continuously.
  • the delivery lumen 31 is disposed on the central axis X of the catheter 10, the therapeutic substance is released from the center of the distal end of the catheter 10, and the administration uniformity can be maintained.
  • the therapeutic substance delivered from the catheter 10 into the brain parenchyma is effectively guided and diffused between the brain cortex while maintaining the pressure gradient.
  • the supply of the therapeutic substance by the syringe 50 is stopped, the catheter 10 is removed, and the treatment is completed.
  • the medical instrument 1 allows a therapeutic substance (substance) to be inserted into a living tissue by inserting it into a non-lumen region that is not a biological lumen (blood vessel, vessel, ureter, etc.).
  • a catheter 10 having a delivery lumen 31 to be delivered and disposed through the central axis X to deliver a therapeutic substance, and four distal closure lumens 32 closed at the distal end;
  • a plurality of stylet main body portions inserted through the distal end closing lumen 32 while maintaining the uniformity of administration / delivery of the therapeutic substance from the distal end of the catheter 10 by the delivery lumen 31 penetrating on the central axis X. 21 can provide rigidity to the catheter 10.
  • the distal end closing lumen 32 is not disposed on the central axis X, but by providing a plurality of the distal end closing lumens 32, it is possible to suppress a bias in the ease of bending due to the direction of the acting force, and to secure sufficient rigidity. It is possible to reach the part with high accuracy.
  • distal end closing lumen 32 is closed at the distal end, air can be prevented from being mixed into the living body, and even when the stylet body 21 is removed from the distal closing lumen 32, the tissue fluid of the living body is closed at the distal end. The load on the living tissue can be suppressed as much as possible without flowing into the lumen 32.
  • the plurality (four) of the stylet main body portions 21 are connected to each other at the base end portion by the stylet hub portion 22, they can be operated simultaneously while maintaining the positional relationship of the plurality of stylet main body portions 21, Operability is improved.
  • the plurality (four) of the stylet main body portions 21 are evenly arranged in the circumferential direction around the central axis X of the catheter 10, the ease of bending of the stylet main body portion 21 depending on the direction of the acting force is improved.
  • the bias can be suppressed to the maximum, and the catheter 10 can reach the target site with high accuracy.
  • the catheter 10 can be given the maximum rigidity.
  • the stylet body 21 is made of a non-magnetic material, halation can be prevented during MRI imaging.
  • the catheter 10 since the catheter 10 is used for convection-enhanced delivery of a therapeutic substance (substance) to the tumor, the catheter 10 can be inserted with high precision up to the target position in the region where the tumor is formed, and the tumor is treated. It becomes possible to deliver the substance for use effectively.
  • the catheter 10 is used for convection increased delivery of a therapeutic substance (substance) to the brain, the catheter 10 can be inserted with high accuracy up to the target position of the brain, and the therapeutic substance to the brain is effective. Delivery is possible.
  • the present invention is not limited to the above-described embodiment, and various modifications can be made by those skilled in the art within the technical idea of the present invention.
  • four tip closing lumens 32 and four stylet body portions 21 are provided, but the number of tip closing lumens and stylet body portions is not limited as long as it is two or more.
  • two tip closing lumens 32A and two stylet main body portions 21A may be provided around the delivery lumen 31A, and the modification shown in FIG.
  • three tip closing lumens 32B and three stylet main body portions 21B may be provided around the delivery lumen 31B.
  • the tendency to bend due to the direction of the acting force is less likely to occur, but if too many, the rigidity of each stylet body part becomes extremely small, Since the operability is lowered and it is difficult to actually form the tip closing lumen, it is preferable to use two to four. Since the number of stylet main body portions is 2 to 4, it is possible to efficiently suppress a deviation in the ease of bending due to the direction of the acting force.
  • the cross-sectional shapes of the tip closing lumens 32C and 32D and the stylet main body portions 21C and 21D may be arcuate.
  • the stylet main body portions 21C and 21D have lengths A1 and A2 in the radial direction from the central axis X in the cross section orthogonal to the central axis X of the catheter, and lengths B1 and B2 in the direction orthogonal to the radial direction. Therefore, the delivery lumens 31C and 31D for delivering the therapeutic substance can be widely secured while obtaining a sufficient bending rigidity.
  • the cross-sectional shapes of the tip closing lumen 32E and the stylet main body 21E may be rectangular.
  • the stylet body 21E is sufficiently bent because the length A3 in the radial direction from the central axis X is shorter than the length B3 in the direction perpendicular to the radial direction in the cross section orthogonal to the central axis X of the catheter. It is possible to secure a wide delivery lumen 31E for delivering a therapeutic substance while obtaining rigidity.
  • the tubular portion 60 of the catheter may have a tapered portion 63 between which the outer diameter gradually decreases toward the distal end side between the distal end portion 61 and the proximal end portion 62.
  • the distal end portion 61 of the tubular portion 60 has an outer diameter smaller than that of the proximal end portion 62.
  • the taper portion 63 preferably gradually decreases with an inclination angle ⁇ of 2 ° to 60 ° with respect to the central axis X of the catheter, and more preferably gradually decreases with an inclination angle ⁇ of 2 ° to 45 °. Formed. If the inclination angle ⁇ is too large, the brain parenchyma will be damaged, and if the inclination angle ⁇ is too small, the effect of backflow at the tapered portion 63 will be reduced. In FIG. 8, only one tapered portion 63 is provided, but a plurality of tapered portions 63 may be provided along the central axis X of the catheter. Instead of the tapered portion 63, one or a plurality of step portions whose outer diameter decreases in a direction perpendicular to the central axis X of the catheter may be provided.
  • the medical device 1 delivers a therapeutic substance to a brain tumor
  • the delivery site is not limited to the tumor, and for example, the liver, pancreas, gallbladder, breast, uterus, large intestine It may be a living tissue other than the brain, such as.
  • the medical instrument 1 can be inserted into a non-luminal region that is not a biological lumen (blood vessel, vessel, ureter, etc.) and deliver a substance into a living tissue in the non-luminal region.
  • 1 medical instrument 10 catheter, 20 Stylet, 21, 21A, 21B, 21C, 21D, 21E Stylet body, 22 Stylet hub, 30, 60 tubular section, 31, 31A, 31B, 31C, 31D, 31E delivery lumen; 32, 32A, 32B, 32C, 32D, 32E Tip closing lumen, 40 catheter hub, 42 proximal opening, 61 Tip, 62 proximal end, 63 taper part, X central axis, ⁇ Tilt angle.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

L'invention fournit un instrument pour traitement médical qui permet d'amener avec une haute précision jusqu'à une région cible, et en limitant autant que possible l'impact sur un tissu biologique, un cathéter acheminant à l'intérieur d'un tissu biologique une substance par insertion dans une région sans lumière du tissu biologique. Plus précisément, l'instrument pour traitement médical (1) destiné à acheminer cette substance à l'intérieur du tissu biologique par insertion dans une région sans lumiére du tissu biologique, possède : un cathéter (10) dans lequel sont formés un lumen d'acheminement (31) disposé de manière à passer au travers d'un axe central (X) afin d'acheminer à l'intérieur du tissu biologique ladite substance, et au moins deux lumen à extrémité avant fermée (32) dont les côtés extrémité avant sont fermés ; et au moins deux éléments âme (21) pouvant être insérés dans les lumen à extrémité avant fermée (32) depuis le côté extrémité de base dudit cathéter (10).
PCT/JP2013/054272 2013-02-21 2013-02-21 Instrument pour traitement médical Ceased WO2014128875A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2013/054272 WO2014128875A1 (fr) 2013-02-21 2013-02-21 Instrument pour traitement médical

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2013/054272 WO2014128875A1 (fr) 2013-02-21 2013-02-21 Instrument pour traitement médical

Publications (1)

Publication Number Publication Date
WO2014128875A1 true WO2014128875A1 (fr) 2014-08-28

Family

ID=51390705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/054272 Ceased WO2014128875A1 (fr) 2013-02-21 2013-02-21 Instrument pour traitement médical

Country Status (1)

Country Link
WO (1) WO2014128875A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11298043B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519693A (ja) * 2002-03-12 2005-07-07 ジル，スティーブン，ストレトフィールド 大脳内適用用カテーテルおよびガイドチューブ
JP2006035001A (ja) * 2003-04-28 2006-02-09 Yutaka Suzuki 瘻孔用カテーテルキット

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519693A (ja) * 2002-03-12 2005-07-07 ジル，スティーブン，ストレトフィールド 大脳内適用用カテーテルおよびガイドチューブ
JP2006035001A (ja) * 2003-04-28 2006-02-09 Yutaka Suzuki 瘻孔用カテーテルキット

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11298043B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US12318183B2 (en) 2016-08-30 2025-06-03 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system

Similar Documents

Publication Publication Date Title
CA2668266C (fr) Catheter produisant moins de reflux dans l'administration tissulaire ciblee d'un agent therapeutique
US7766875B2 (en) Catheter for reduced reflux in targeted tissue delivery of a therapeutic agent
DK2152346T3 (en) Konvektionsforstærket indgivelseskateter with removable support element
US9089667B2 (en) Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
JP4604022B2 (ja) 運搬促進デリバリー法による組織および腫瘍への液体の投与のための携帯用装置
US6368315B1 (en) Composite drug delivery catheter
D’Amico et al. Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model
US12396750B2 (en) Adjustable stepped cannula
US9402974B2 (en) Optimized intracranial catheters for convection-enhanced delivery of therapeutics
Mehta et al. Current status of intratumoral therapy for glioblastoma
CN118178841A (zh) 利用球囊实现药物输送的装置、给药装置及微创医学系统
JP2015015988A (ja) 医療用器具
WO2014128875A1 (fr) Instrument pour traitement médical
WO2014128881A1 (fr) Appareil médical
WO2014128824A1 (fr) Instrument pour traitement médical
JP6193111B2 (ja) 医療用器具
WO2015093274A1 (fr) Catheter d'administration de substances
Hall Convection-enhanced delivery: neurosurgical issues
JP6228485B2 (ja) 挿入部材固定具
JP2015015989A (ja) 医療用器具
Naidoo et al. Convection-Enhanced Drug Delivery in the Central Nervous System
US20100047210A1 (en) Systems and Methods for Positioning of Needles and Other Devices Within Body Tissue
JP2019524253A (ja) 局所領域注入のための植込み可能な医療装置
Laine et al. Brain Tumors: Convection-Enhanced Delivery of Drugs (Method)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13875541

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13875541

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP